On July 25, 2024, ITF Therapeutics LLC, the U.S.-based rare disease commercial arm of Italfarmaco, today announced the U.S. commercial launch of DUVYZAT™ (givinostat), a histone deacetylase inhibitor, for the treatment of patients six years of age and older with Duchenne muscular dystrophy (DMD). DUVYZAT was approved by the U.S. Food and Drug Administration (FDA) on March 21, 2024.
Read more about this update by clicking here to view their full press release.
